All Oncology News

The FDA's Molecular and Clinical Genetics advisory committee has unanimously supported the safety, efficacy, and positive risk-benefit profile of the noninvasive stool-based DNA test Cologuard in a 10-0 vote.

Ceritinib (LDK378) demonstrated an ORR of 58% and a median PFS of 7 months as a treatment for patients with ALK-positive non-small cell lung cancer.

It looks like trouble continues for a bill that would delay payment cuts to physicians who treat Medicare patients for one year

The blood-based colorectal cancer (CRC) screening test Epi proColon passed the scrutiny of the FDA's Molecular and Clinical Genetics advisory panel in a close 5-4 vote with 1 abstention in support of the claim that the test's benefits outweigh its risks

Practice managers who need to understand the ins and outs of Medicare's resource-based relative value scale (RBRVS) can purchase an updated physician guide from the American Medical Association.

A physician's confidence level in his genomic knowledge plays a significant role in attitudes towards genomic tests, especially in tests that look for changes in DNA that are taken from patients' tumor samples

Small practices face all the difficulties of health IT implementation without the benefit of big budgets and numerous staff to diffuse the burdens, according to EHRIntelligence.com.

Leader in Supportive Oncology at Perlmutter Cancer Center at NYU Langone Medical Center to Take Leadership Position with the American College of Physicians.

Patients were no more likely to switch away from lower-tiered physicians than higher-tiered physicians within their health plan, especially if the physician was considered the patient's personal doctor

The MAGE-A3-specific immunotherapeutic GSK1572932A failed to significantly extend disease-free survival (DFS) in patients with resected nonmetastatic non-small cell lung cancer (NSCLC) who tested negative for a specific gene expression signature

Efforts to evaluate cancer survivorship programs are a daunting task according to a technical brief issued by the Agency for Healthcare Research and Quality.

The oncolytic immunotherapeutic vaccine talimogene laherparepvec (T-VEC) promoted tumor shrinkage in 64% of patients with advanced melanoma, including a marked reduction in the size of uninjected metastatic lesions

After months of wrangling, a call for a vote by House Majority Leader Eric Cantor on an amended version of the Sustainable Growth Rate (SGR) Repeal and Medicare Provider Payment Modernization Act of 2014 (H.R. 4015).

Nivolumab, a PD-1-specific antibody, has been shown to produce long-term remissions with limited toxicity in patients with advanced melanoma, according to results from one of the longest follow ups to examine the drug.

An exceptional responder with advanced urothelial carcinoma experienced a complete radiologic response lasting 13.8 months following treatment with the combination of everolimus (Afinitor) and pazopanib.

Converting from ICD-9 to ICD-10 will result in information and financial losses to providers, report researchers from the University of Illinois at Chicago

The FDA has placed a full clinical hold on the development of the investigational telomerase inhibitor imetelstat following concerns over consistent low-grade liver function test (LFT) abnormalities

Evidence that demonstrates how best to implement newer value-based purchasing (VBP) programs like accountable care organizations (ACOs) and bundled payments is lacking

The US cancer care system is faced with increasing cuts to Medicare payments, the prospect of a dramatic increase in the number of patients with cancer, and proportionately fewer oncology specialists to treat them.

More oncology practices are looking to advanced practice nurses and other non-physician providers to meet the needs of their cancer patients.

New research suggests that spending on anticancer agents is moderating, going against national trends that suggest an uptick in the US prescription drug expenditures this year.

Ruxolitinib, a JAK1/2 inhibitor, is the first treatment to demonstrate efficacy in a phase III trial for patients with polycythemia vera (PV), a chronic, incurable blood cancer with limited treatment options

With the adoption of a patient engagement initiative, Gwinnett Medical Center in Atlanta was able to improve the billing experience for 86% of patients surveyed.

Repealing the sustainable growth rate (SGR) formula, a mechanism Congress enacted in 1997 to limit Medicare costs, is going to leave taxpayers with a bill of $60 billion from 2014 through 2019, and a total of $138 billion through 2024.

An immunotherapy drug for the treatment of prostate cancer, approved in the US in 2010, will soon be available in Europe.

Bucking a trend reported for many years, new compensation data suggest the gap between what primary care physicians are paid and what medical and surgical specialists are paid is decreasing.

A phase III study exploring the MET inhibitor onartuzumab as a treatment for patients with NSCLC is being stopped, following an interim analysis that suggested a lack of clinically meaningful efficacy.

Hospitals and medical centers that provide chemotherapy infusion services to their cancer patients on an outpatient basis generally get paid more than oncologists and hematologists who provide the same services in a private office.

Improvements in quality of care and reductions in hospitalizations were minimal

More and more solo practices are facing a transformation that is neither small nor simple in the current accountable care environment.